Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis

  • François Roubille
  • Olivier Lairez
  • Nathan Mewton
  • Gilles Rioufol
  • Sylvain Ranc
  • Ingrid Sanchez
  • Thien Tri Cung
  • Meyer Elbaz
  • Christophe Piot
  • Michel Ovize
Original Contribution


Antiplatelet agents have been extensively used in acute coronary syndromes and improve clinical outcome in STEMI patients. Previous experimental studies of the impact of antiplatelet agents on infarct size have been equivoqual. We questioned whether clopidogrel might reduce infarct size in STEMI patients, independently of any antithrombotic effect, by activating a post-conditioning-like myocardial protection. We retrospectively analyzed three recent controlled, randomized, proof of concept clinical trials aimed at determining whether PCI post-conditioning might attenuated infarct size in STEMI. We addressed whether clopidogrel (300–600 mg before angioplasty) might have influenced infarct size using a multivariable linear regression analysis with infarct size as the continuous outcome variable and age, clopidogrel and GP IIb/IIIa inhibitors, post-conditioning, area at risk, ischemia time, coronary thrombectomy and final TIMI flow, as covariates. In this population of 88 STEMI patients, ischemic post-conditioning and clopidogrel administration were the only two therapeutic independent predictors of the final infarct size as determined by cardiac enzymes release (p = 0.005 and p < 0.0001, respectively) This retrospective analysis supports the proposal that clopidogrel attenuates lethal reperfusion injury.


Infarction Ischemia Reperfusion Clopidogrel 



The authors express their gratitude to all Clinical Research Assistants who have been involved in these post-conditioning trials (V.Prost, I.Sahraoui), as well as to Céline Giraud for statistics. Nathan Mewton was a recipient of a grant from the Fédération Française de Cardiologie. Post-conditioning studies have been supported by grants from the Hospices Civils de Lyon and from the french PHRC (Programme National de Recherche Clinique).

Conflict of interest



  1. 1.
    Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M (2005) Postconditioning inhibits mitochondrial permeability transition. Circulation 111:194–197. doi: 10.1161/01.CIR.0000151290.04952.3B PubMedCrossRefGoogle Scholar
  2. 2.
    Baks T, van Geuns RJ, Biagini E, Wielopolski P, Mollet NR, Cademartiri F, Boersma E, van der Giessen WJ, Krestin GP, Duncker DJ, Serruys PW, de Feyter PJ (2005) Recovery of left ventricular function after primary angioplasty for acute myocardial infarction. Eur Heart J 26:1070–1077. doi: 10.1093/eurheartj/ehi131 PubMedCrossRefGoogle Scholar
  3. 3.
    Barrabès JA, Garcia-Dorado D, Mirabet M, Inserte J, Agulo L, Soriano B, Massaguer A, Padilla F, Lidon RM, Soler-Soler J (2005) Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia. J Am Coll Cardiol 45:293–299. doi:10.1016/j.jacc.2004.09.068 Google Scholar
  4. 4.
    Barrabès JA, Garcia-Dorado D, Mirabet M, Lidon RM, Soriano B, Ruiz-Meana M, Pizcueta P, Blanco J, Puigfel Y, Soler-Soler J (2002) Lack of effect of glycoprotein IIb/IIIa blockade on platelet or polymorphonuclear leukocyte accumulation and on infarct size after transient coronary occlusion in pigs. J Am Coll Cardiol 39:157–165. doi:10.1016/S0735-1097(01)01712-0 Google Scholar
  5. 5.
    Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA, CHAMPION PLATFORM Investigators (2009) Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361:2330–2341PubMedCrossRefGoogle Scholar
  6. 6.
    Boengler K, Schulz R, Heusch G (2009) Loss of cardioprotection with ageing. Cardiovasc Res 83:247–261. doi: 10.1093/cvr/cvp033 PubMedCrossRefGoogle Scholar
  7. 7.
    Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, Antoniucci D (2002) Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 106:2351–2357. doi: 10.1161/01.CIR.0000036014.90197.FA PubMedCrossRefGoogle Scholar
  8. 8.
    Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS (2005) COMMIT (clopidogrel and metoprolol in myocardial infarction trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621. doi: 10.1016/S0140-6736(05)67660-X PubMedCrossRefGoogle Scholar
  9. 9.
    Diehl P, Olivier C, Halscheid C, Helbing T, Bode C, Moser M (2010) Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Basic Res Cardiol 105:379–387PubMedCrossRefGoogle Scholar
  10. 10.
    Feild BJ, Russell RO Jr, Dowling JT, Rackley CE (1972) Regional left ventricular performance in the year following myocardial infarction. Circulation 46:679–689. doi: 10.1161/01.CIR.46.4.679 PubMedCrossRefGoogle Scholar
  11. 11.
    Freixa X, Bellera N, Ortiz-Pérez JT, Jiménez M, Paré C, Bosch X, De Caralt TM, Betriu A, Masotti M (2012) Ischaemic postconditioning revisisted: lack of effects on infarct size following primary percutaneous coronary intervention. Eur Heart J 33:103–112. doi: 10.1093/eurheartj/ehr297 PubMedCrossRefGoogle Scholar
  12. 12.
    Gibbons RJ, Valeti US, Araoz PA, Jaffe AS (2004) The quantification of infarct size. J Am Coll Cardiol 44:1533–1542. doi: 10.1016/j.jacc.2004.06.071 Google Scholar
  13. 13.
    Heusch G (2012) Reduction of infarct size by ischaemic post-conditioning in humans: fact or fiction? Eur Heart J 33:13–15. doi: 10.1093/eurheartj/ehr341 PubMedCrossRefGoogle Scholar
  14. 14.
    Heusch G, Kleinbongard P, Skyschally A, Levkau B, Schulz R, Erbel R (2012) The coronary circulation in cardioprotection: more than just one confounder. Cardiovasc Res 94:237–245. doi: 10.1093/cvr/cvr271 PubMedCrossRefGoogle Scholar
  15. 15.
    Hirata Y, Umemura K, Uematsu T, Nakashima M (1995) An experimental myocardial infarction model in the rat and its properties. Jpn J Pharmacol 67:51–57. doi:10.1254/jjp.67.51 Google Scholar
  16. 16.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349–360Google Scholar
  17. 17.
    Krijnen PAJ, Hahn NE, Kholova′ I, Baylan U, Sipkens JA, van Alphen FP, Vonk ABA, Simsek S, Meischl C, Schalkwijk CG, van Buul JD, van Hinsbergh VWM, Niessen HWM (2012) Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients. Basic Res Cardiol 107:233. doi: 10.1007/s00395-011-0233-5 PubMedCrossRefGoogle Scholar
  18. 18.
    Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK (2011) Ting HH (2011) ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation 124:2574–2609. doi: 10.1161/CIR.0b013e31823ba622 PubMedCrossRefGoogle Scholar
  19. 19.
    Mewton N, Elbaz M, Piot C, Ovize M (2011) Infarct size reduction in patients with STEMI: why we can do it! J Cardiovasc Pharmacol Ther 16:298–303. doi: 10.1177/1074248411412379 PubMedCrossRefGoogle Scholar
  20. 20.
    Miller TD, Christian TF, Hopfenspirger MR, Hodge DO, Gersh BJ, Gibbons RJ (1995) Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. Circulation 92:334–341. doi: 10.1161/01.CIR.92.3.334 PubMedCrossRefGoogle Scholar
  21. 21.
    Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM, TRITON-TIMI 38 investigators (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373:723–731. doi: 10.1016/S0140-6736(09)60441-4 PubMedCrossRefGoogle Scholar
  22. 22.
    Montoro-García S, Shantsila E, Marín F, Blann A, Lip GYH (2011) Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. Basic Res Cardiol 106:911–923. doi: 10.1007/s00395-011-0198-4 PubMedCrossRefGoogle Scholar
  23. 23.
    Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R (2010) Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the working group of cellular biology of the heart of the European society of cardiology. Cardiovasc Res 87:406–423. doi: 10.1093/cvr/cvq129 PubMedCrossRefGoogle Scholar
  24. 24.
    Patti G, Bárczi G, Orlic D, Mangiacapra F, Colonna G, Pasceri V, Barbato E, Merkely B, Édes I, Ostojic M, Wijns W, Di Sciascio G (2011) Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST segment elevation myocardial infarction: results from the ARMYDA-6 MI (antiplatelet therapy for reducton of myocardial damage during angioplasty-myocardial infarction) randomized study. J Am Coll Cardiol 58:1592–1599. doi: 10.1016/j.jacc.2011.06.044 Google Scholar
  25. 25.
    Piot C, Croisille C, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, André-Fouët X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M (2008) Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359:473–481PubMedCrossRefGoogle Scholar
  26. 26.
    Schäfer A, Fraccarollo D, Pförtsch S, Loch E, Neuser J, Vogt C, Bauersachs J (2011) Clopidogrel improves endothelial function and NO bioavailability by sensitizing adenylyl cyclase in rats with congestive heart failure. Basic Res Cardiol 106:485–494. doi: 10.1007/s00395-011-0153-4 PubMedCrossRefGoogle Scholar
  27. 27.
    Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, Downey J, Gibbons RJ, Gottlieb RA, Heusch G, Jennings RB, Lefer DJ, Mentzer RM, Murphy E, Ovize M, Ping P, Przyklenk K, Sack MN, Vander Heide RS, Vinten-Johansen J, Yellon DM (2011) New horizons in cardioprotection: recommendations from the 2010 national heart, lung, and blood institute workshop. Circulation 124:1172–1179. doi: 10.1161/CIRCULATIONAHA.111.032698 PubMedCrossRefGoogle Scholar
  28. 28.
    Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L’Huillier I, Aupetit JF, Bonnefoy E, Finet G, Andre-Fouet X, Ovize M (2005) Postconditioning the human heart. Circulation 112:2143–2148. doi: 10.1161/CIRCULATIONAHA.105.558122 PubMedCrossRefGoogle Scholar
  29. 29.
    Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L, PLATO Study Group (2010) Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation 122:2131–2141. doi: 10.1161/CIRCULATIONAHA.109.927582 PubMedCrossRefGoogle Scholar
  30. 30.
    Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM, for the INFUSE-AMI investogators (2012) Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 307:1817–1826. doi: 10.1001/jama.2012.421 PubMedCrossRefGoogle Scholar
  31. 31.
    Tarantini G, Favaretto E, Perazzolo Marra M, Frigo AC, Napodano M, Cacciavillani L, Giovagnoni A, Renda P, De Biasio V, Plebani M, Mion M, Zaninotto M, Isabella G, Bilato C, Iliceto S (2012) Postconditioning during coronary angioplasty in acute myocardial infarction: the POST-AMI trial. Int J Cardiol. doi: 10.1016/j.ijcard.2012.03.136 Google Scholar
  32. 32.
    Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, Cung TT, Bonnefoy E, Angoulvant D, Aupetit JF, Finet G, Andre-Fouet X, Macia JC, Raczka F, Rossi R, Itti R, Kirkorian G, Derumeaux G, Ovize M (2008) Long-term benefit of postconditioning. Circulation 117:1037–1044. doi: 10.1161/CIRCULATIONAHA.107.729780 PubMedCrossRefGoogle Scholar
  33. 33.
    Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM (2004) Postconditioning: a form of “Modified Reperfusion” protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95:230–232. doi: 10.1161/01.RES.0000138303.76488.fe PubMedCrossRefGoogle Scholar
  34. 34.
    Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ, Penn MS (2010) Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost 104:609–617. doi:10.1160/TH09-12-0823 Google Scholar
  35. 35.
    Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Uva MS, Taggart D (2010) Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 31:2501–2555. doi: 10.1093/eurheartj/ehq277 PubMedCrossRefGoogle Scholar
  36. 36.
    Yang X-M, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV (2004) Multiple, brief coronary occlusions during early reperfusion protect hearts by targeting cell signaling pathways. J Am Coll Cardiol 44:1103–1110. doi: 10.1016/j.jacc.2004.05.060 Google Scholar
  37. 37.
    Yang YJ, Zhao JL, You SJ, Wu YJ, Jing ZC, Yang WX, Meng L, Wang YW, Gao RL (2006) Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. Heart 92:1131–1137. doi: 10.1136/hrt.2005.077164 PubMedCrossRefGoogle Scholar
  38. 38.
    Zhao Z-Q, Corvera JS, Halkos ME, Kerendi F, Wang N-P, Guyton RA, Vinten-Johansen J (2003) Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol 285:H579–H588. doi: 10.1152/ajpheart.01064.2002 Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • François Roubille
    • 3
    • 4
  • Olivier Lairez
    • 5
  • Nathan Mewton
    • 1
    • 2
  • Gilles Rioufol
    • 1
  • Sylvain Ranc
    • 2
  • Ingrid Sanchez
    • 2
  • Thien Tri Cung
    • 3
    • 4
  • Meyer Elbaz
    • 5
  • Christophe Piot
    • 3
    • 4
  • Michel Ovize
    • 1
    • 2
    • 6
  1. 1.Inserm U1060 (CarMeN)LyonFrance
  2. 2.CIC de Lyon, service d’Exploration Fonctionnelles Cardiovasculaires, Hospices Civils de LyonUniversité Claude Bernard Lyon1LyonFrance
  3. 3.Inserm U661MontpellierFrance
  4. 4.Hopital Arnaud de VilleneuveUniversité de Montpellier I and IIMontpellierFrance
  5. 5.Service de Cardiologie, Hôpital RangueuilUniversity Paul SabatierToulouseFrance
  6. 6.Hôpital Cardiologique et Pneumologique Louis PradelLyon Cedex 03France

Personalised recommendations